Pharmacogenomics promises clearer efficacy signals, fewer safety events, and stronger labels—yet it rarely features in clinical trials. Despite strong evidence, adoption remains slow, fragmented, and operationally complex. This piece explores why PGx still struggles to become…
Read more →
